Improved Open-Access NMR for the Synthetic and Analytical Chemistry Laboratories
Nuclear magnetic resonance spectroscopy is a well-established technique popular for being quantitative by nature and giving unparalleled structural information of both solid and liquid samples. The drawback is that it is perceived as an expensive, difficult to use technique in the hands of few specialists. Due to advances in hardware, software, automation and workflow integration, this is no longer true.
NMR can nowadays be deployed to an open access environment in the chemistry and analytical laboratories. Reduced footprint NMR instruments are no longer installed in the basement, but in any floor, surrounded by other analytical instrumentation, fume cupboards and benches. Improved software makes data acquisition and processing of complex samples and experiments straightforward for even novice users.
What You Will Discover
In this webinar Dr. Mark Zell, Takeda Pharmaceuticals, and Dr. Anna Codina, Bruker BioSpin, will discuss the benefits of NMR as walk-up instrument in the pharmaceutical industry.
Key Points
- Examples of NMR instrumentation in walk-up labs
- Applications of the open access NMR for pharmaceutical chemical and analytical R&D
- Benefits and return of investment of the open access NMR
Who should attend
This webinar will be of interest to those looking to extend and improve their analytical capabilities, heads of medicinal chemistry, analytical and chemical R&D, laboratory managers and expert users of complementary technologies. It is especially dedicated for those seeking to understand the return of investment in NMR in emerging, growing markets.
Speakers
Dr. Mark T. Zell
Associate Scientific Fellow and Structural Characterization Team Leader, Takeda
Mark Zell earned his Bachelor of Science degree from the University of Wisconsin – Milwaukee in 1995 and his Ph.D. in Analytical Chemistry from the University of Minnesota in 2000 under the direction of Professor Eric Munson. Following completion of his graduate studies, he worked briefly as a Research Scientist with Procter & Gamble Pharmaceuticals. In 2002, he joined Pfizer in Ann Arbor, Michigan working to develop the structure elucidation capabilities in the drug development organization. In 2007, he moved to the Pfizer facility in Groton, CT where he advanced to the role of Associate Research Fellow and NMR Team Leader in the Structure Elucidation Group, assisting in the advancement of the Pharmaceutical Sciences Open Access NMR lab, Quantitative NMR for routine use, reaction monitoring, and other NMR tools for project understanding. In 2017, he joined Takeda in Cambridge, Massachusetts as Associate Scientific Fellow and Structural Characterization Group Team Leader. His research interests involve the application of cutting-edge analytical instrumentation for structure elucidation and reaction monitoring. Dr. Zell is also a Courtesy Assistant Professor with the Department of Medicinal Chemistry at the University of Florida, College of Pharmacy, an appointment he has held since 2013. His responsibilities include teaching the courses Pharmaceutical Analysis II and Organic Structure Elucidation.
Anna Codina, Ph.D.
Senior Director Strategy and Business Development, SciY
Anna has a degree in Chemistry and a Ph.D. in Protein NMR from the University of Barcelona, Spain. She undertook her post-doc in protein NMR at the MRC Laboratory of Molecular Biology in Cambridge, UK, and following that worked in the Analytical R&D department of Pfizer for seven years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation. She received a Pfizer Worldwide Achievement Award for the implementation of reaction monitoring by NMR in an open access environment.
She joined Bruker in 2011 and had different roles since including Material Characterisation Laboratory Manager, Product Portfolio Manager and for several years was in charge of driving the Biopharmaceutical business at Bruker BioSpin. Anna recently moved to SciY as Senior Director of Strategy and Business Development.